William L. Heyward, M.D., M.P.H.
President
Dr. William Heyward is a founding member and President of Quattro Clinical Research (QCR). Prior to QCR, Dr. Heyward served as a Commissioned Officer with the U.S. Public Health Service at the Centers for Disease Control and Prevention (CDC) for more than 20 years (1979 - 2000). While at CDC, Dr. Heyward was director of a research field station in Alaska and coordinated epidemiologic and vaccine research on hepatitis B, Haemophilus influenzae type B, pneumococcal disease, and botulism. While serving as Chief of International Activities of CDC's AIDS Program, he was instrumental in developing research collaborations and field sites in Africa (Zaire, Cote d'Ivoire, Burkina Faso, Guinea Bissau), South America (Brazil, Honduras), and Asia (Thailand), and later served as Director of Project SIDA in Kinshasa, Zaire. From 1991 to 1996, Dr. Heyward was detailed to the HIV Vaccine Unit of the World Health Organization's Global Programme on AIDS and the Joint United Nations Programme on AIDS where he coordinated development of HIV vaccine trial sites in Brazil, Uganda, Rwanda, and Thailand. In June of 1995, Dr. Heyward was part of an international team to investigate and control the Ebola epidemic in Kikwit, Zaire. In 1996, he returned to the US to oversee CDC's HIV vaccine development and evaluation program. Following retirement from CDC, Dr. Heyward worked at VaxGen, Inc. (Brisbane, CA) from 2000 to 2004 as Vice President of International Clinical Research. In this capacity, he coordinated the first international phase III efficacy trial of a candidate HIV vaccine in Bangkok, Thailand among 2500 injecting drug users, and assisted the Walter Reed Army Institute for Research and the Thailand Ministry of Public Health in launching a second phase III trial with a "prime-boost" HIV vaccine candidate.  Since founding QCR in 2004, Dr. Heyward has consulted with a number of companies to evaluate HIV and meningococcal vaccines and other therapeutic products.  From 2005 to 2007, Dr. Heyward was a Senior Clinical Consultant to the International Partnership for Microbicides (Silver Spring, MD) to develop a phase I-III trial program of vaginal gel and ring microbicides for the prevention of HIV infection in Africa.

Dr. Heyward has coordinated or assisted multiple large-scale domestic and international clinical trials including a phase IV demonstration project, four phase III efficacy trials, and multiple phase I-II safety and immunogenicity trials. He has served on multiple committees including the International Advisory Group for the Phase III Efficacy Trial of AIDSVAX B/E HIV Vaccine in Bangkok, the U.S. Public Health Service Interagency HIV Vaccine Collaborative Group, the HIV Vaccine Advisory Group of the Joint United Nations Programme on AIDS, the CDC Adult Immunization Workgroup, and others.

He has co-authored over 100 scientific articles including two award winning papers. He has been the recipient of more than a dozen awards, including the Surgeon General's Exemplary Service Medal, the Outstanding Service medal, the Commendation medal, and the U.S. Department of Health and Human Services Secretary's Award for Distinguished Service to the CDC Adult Immunization Workgroup.

Dr. Heyward received his undergraduate degree in Chemistry from Emory University in Atlanta, Georgia, an M.D. from the Medical College of Georgia in Augusta, Georgia, and an M.P.H. from the Johns Hopkins University School of Public Health in Baltimore, Maryland.

Carolyn Gee,
Managing Director, Clinical Development

Carolyn Gee is a founding member of Quattro Clinical Research (QCR).  She has more than 16 years experience in the biotech/pharmaceutical industry.  Prior to joining QCR, Carolyn worked at VaxGen, Inc. as the Senior Manager of International Clinical Research.  She spent approximately 4 years living in Thailand where she served as VaxGen’s focal point coordinating and project managing activities for the first large-scale international Phase III preventive HIV vaccine trial among participating Thai institutions including the Bangkok Metropolitan Administration, Mahidol University and the Thai Ministry of Public Health-U.S. Centers for Disease Control and Prevention Collaboration.  Among her numerous responsibilities, she provided sponsor leadership and guidance on study conduct issues, coordinated field data clean-up, performed data and safety reviews, and managed overall site monitoring.  In addition, she contributed to VaxGen’s clinical infrastructure through development of resourcing plans, working procedures, Standard Operating Procedures, monitoring tools and clinical study materials. Prior to this, Carolyn worked at Shaman Pharmaceuticals and Chiron Corporation where she provided a number of services including project management, contract negotiations, field monitoring, protocol development, Case Report Form and study materials design, and training for Clinical Research Associates. She has extensive experience with Phase I-III domestic and international clinical trials working on preventive vaccines (HIV, herpes simplex virus type II, acellular pertussis, hepatitis B) and other therapeutic areas (gastrointestinal disease, endocrinology).

Since founding QCR in 2004, Carolyn has consulted with a number of companies involved with vaccine research and a Bacterio-Therapeutics company.  From 2005-2007 Carolyn was a Clinical Project Manager Consultant to the International Partnership for Microbicides involved in the development of a phase I-III trial program of vaginal gel and ring microbicides for the prevention of HIV infection in Africa.

Carolyn received her undergraduate degree (B.A.) in psychology with a minor concentration in biology from the University of California, Irvine and a master’s degree (M.Ed.) in counseling and consulting psychology from Harvard University.

Karin Orelind
Managing Director of Clinical Operations

Karin Orelind is a founding member of Quattro Clinical Research (QCR). She has 16 years experience in the pharmaceutical/biotech industry. Prior to joining QCR, Karin was the Associate Director of International Clinical Research at VaxGen, Inc. During her 5 ½ years at VaxGen, Karin was instrumental in setting up the preventive HIV vaccine Phase III trial in 61 sites in North America and Europe. She also oversaw the clinical management of a second Phase III HIV vaccine trial in Bangkok, Thailand which entailed management of Clinical Research Associates, budgets, project plans and timelines and supervision of the Clinical Safety Group. Prior to VaxGen, her experience included various management and operational duties on Phase I-III domestic and international clinical trials on vaccines (herpes simplex virus type II, human papilloma virus, acellular pertussis), infectious diseases, rheumatology, oncology and gastrointestinal disease through her work at Gilead Sciences, SUGEN, Chiron Corporation, Quintiles Pacific, and as a Study Coordinator at Rush Presbyterian St. Luke's Medical Center, Chicago, IL.
 
Since founding QCR in 2004, Karin has consulted with a number of companies performing HIV vaccine research and a Bacterio-Therapeutics company.  From 2005-2007 Karin was a Clinical Project Consultant to the International Partnership for Microbicides (Silver Spring, MD) to develop a phase I-III trial program of vaginal gel and ring microbicides for the prevention of HIV infection in Africa.

Karin received her undergraduate degree (B.A.) in psychology from the University of Wisconsin-Madison.